Article Text

Download PDFPDF
Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer
  1. Jonathan A. Ledermann, BSc, MD, FRCP*,
  2. Christian Marth, MD, PhD,
  3. Mark S. Carey, MD,
  4. Michael Birrer, MD, PhD§,
  5. David D.L. Bowtell, PhD,
  6. Stan Kaye, MD, FRCP,
  7. Iain McNeish, PhD, FRCP*,
  8. Amit Oza, MD,
  9. Giovanni Scambia, MD#,
  10. Gordon Rustin, MD, FRCP*,
  11. Frederick B. Stehman, MD§,
  12. David Gershenson, MD**,
  13. Gillian Thomas, MD**,
  14. Els Berns, MD,,
  15. Antonio Casado, MD,,
  16. Nelleke Ottevanger, MD,,
  17. Felix Hilpert, MD§§,
  18. Byoung-Gie Kim, MD, PhD∥∥,
  19. Aikou Okamoto, MD, PhD¶¶,
  20. Monica Bacon, RN##,
  21. Henry Kitchener, MD* and
  22. Gavin C.E. Stuart, MD, FRCSC
  1. * MRC/NCRI, UK;
  2. AGO, Austria;
  3. NCIC-CTG, Canada;
  4. § GOG;
  5. ANZGOG, Australia and New Zealand;
  6. SGCTG, Scotland;
  7. # MITO, Italy;
  8. ** National Cancer Institute;
  9. †† EORTC-GCG;
  10. ‡‡ DGOG, The Netherlands;
  11. §§ AGO OVAR, Germany;
  12. ∥∥ KGOG, Korea;
  13. ¶¶ JGOG, Japan; and
  14. ## GCIG.
  1. Address correspondence and reprint requests to Jonathan A. Ledermann, BSc, MD, FRCP, UCL/H Comprehensive Biomedical Research Centre, Cancer Research UK and UCL Cancer Trials Centre, 90 Tottenham Court Rd, London, W1T 4TJ, United Kingdom. E-mail: j.ledermann{at}


There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.

  • Molecular agents
  • Ovarian cancer
  • Clinical trials

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.